AI Analysis | Feedback

Here are 1-3 brief analogies for Tarsus Pharmaceuticals (TARS):

• A specialized biotech, similar to Vertex Pharmaceuticals (VRTX), but dedicated to innovative treatments for specific eye and skin conditions.
• A smaller, focused Regeneron Pharmaceuticals (REGN), developing specialized drugs for unmet needs in eye and skin diseases.

AI Analysis | Feedback

• XDEMVY (Lotilaner ophthalmic solution): The first and only FDA-approved treatment for *Demodex* blepharitis.
• TP-04 (Lotilaner topical gel): An investigational therapeutic currently in clinical development for rosacea.
• TP-05 (Oral Lotilaner): An investigational therapeutic currently in clinical development for the prevention of Lyme disease.

AI Analysis | Feedback

Tarsus Pharmaceuticals (TARS) Major Customers

Tarsus Pharmaceuticals (TARS) primarily sells its products, such as XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis, to pharmaceutical wholesalers. These wholesalers then distribute the products to retail pharmacies, hospitals, and other healthcare providers.

Based on their public filings, the major customer companies (pharmaceutical wholesalers) include:

• AmerisourceBergen Corporation (NYSE: COR)
• Cardinal Health, Inc. (NYSE: CAH)
• McKesson Corporation (NYSE: MCK)

AI Analysis | Feedback

AI Analysis | Feedback

Bobak Azamian, M.D., Ph.D. Chief Executive Officer and Chairman

Bobby co-founded Tarsus Pharmaceuticals, Inc. with Michael Ackermann in November 2016 and has served as its President and CEO since September 2018, and as Chairman since December 2022. He has co-founded and led other novel therapeutics companies, including Vibrato Medical and Metavention, and currently serves on the board of Vibrato Medical and as Chairman of the board of Osanni Bio. Prior to his entrepreneurial career, Dr. Azamian began his biotechnology career at Versant Ventures and Third Rock Ventures, where he was an investor and board observer for various life sciences companies. He trained as a physician scientist, completing his residency in internal medicine and serving as an attending hospitalist at Brigham and Women's Hospital. He received an M.D. from Harvard Medical School (Harvard-MIT Health Sciences and Technology) and a Ph.D. in chemistry from Oxford University as a Rhodes Scholar.

Jeff Farrow Chief Financial Officer and Chief Strategy Officer

Jeff Farrow was appointed Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, effective April 2023, replacing Leo Greenstein. Prior to joining Tarsus, Jeff served as Chief Financial Officer at Global Blood Therapeutics, Inc. (GBT), where he played a significant role in securing regulatory approval and commercializing Oxbryta® for sickle cell disease. Before GBT, he was CFO at ZS Pharma, a company that developed a therapy for hyperkalemia before its acquisition by AstraZeneca. He also served as CFO of Hyperion Therapeutics, Inc., a pharmaceutical company that successfully commercialized Ravicti® for urea cycle disorders. Earlier in his career, Jeff worked in the audit practice of KPMG LLP.

Sesha Neervannan, Ph.D. Chief Operating Officer

Sesha Neervannan has over 25 years of global drug development experience with novel therapeutics. Before joining Tarsus, he was a Senior Vice President of Global Pharmaceutical Development at Allergan (an AbbVie company), where he oversaw product development for small molecules and biologics and contributed to regulatory filings and approvals for multiple ocular, oral, and dermal product candidates. His work at Allergan included novel intra-ocular, sustained-release injectables (Ozurdex®, Durysta®), a multidose non-preserved drug product (Restasis® Multidose), topical dermal products (Rhofade® Cream, Aczone® Gel 7.5%), and several Rx and OTC topical ophthalmic products. Prior to Allergan, he was Director, Pharmaceutics R&D, at Amgen Inc.

Aziz Mottiwala Chief Commercial Officer

Aziz Mottiwala has over 20 years of leadership experience in the biopharmaceutical industry, covering all aspects of commercialization in several therapeutic areas, with over 10 years in the eye care space. Before joining Tarsus, Aziz was Chief Commercial Officer at Opiant Pharmaceuticals, overseeing commercial strategy for the company's addiction medicine portfolio. Prior to that, he was Senior Vice President and Head of Commercial at Avanir Pharmaceuticals.

Elizabeth Yeu, M.D. Chief Medical Officer

Elizabeth Yeu has over 20 years of clinical ophthalmology and eye care leadership experience. Before becoming CMO, Dr. Yeu served as Tarsus' Chief Medical Advisor since 2020 and as a Board member since 2021. She is also a partner at Virginia Eye Consultants and an Executive Committee member and current Secretary for the American Society of Cataract and Refractive Surgery (ASCRS), and is slated to be President of the ASCRS in 2023. Dr. Yeu serves as Board Chair of STAAR Surgical.

AI Analysis | Feedback

1. Heavy Reliance on a Single Commercial Product and Limited Operating History: Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company with a limited operating history, and its financial performance is substantially dependent on the success of its flagship product, XDEMVY (lotilaner ophthalmic solution) 0.25%, for Demodex blepharitis. Any factors affecting XDEMVY's market acceptance, such as competition, regulatory changes, or manufacturing issues, could significantly impact the company's revenue and overall financial health.
2. Ongoing Significant Losses and Negative Cash Flows: Since its inception, Tarsus Pharmaceuticals has consistently incurred significant losses and negative cash flows from operations, a trend it anticipates will continue for the foreseeable future. While the company currently maintains cash reserves, these financial challenges necessitate careful resource management and may require Tarsus to secure additional funding to sustain operations, advance its pipeline, and fund commercialization efforts, particularly given its intensive research and development (R&D) and marketing expenditures.
3. Inherent Risks of Clinical Drug Development: The development of Tarsus's pipeline product candidates, such as TP-04 for ocular rosacea and TP-05 for Lyme disease, is a lengthy, expensive, and inherently risky process with uncertain timelines and outcomes. Delays or failures in clinical trials to meet safety or efficacy endpoints, or an inability to secure necessary regulatory approvals, would adversely affect future revenue streams and the company's long-term growth prospects. Additionally, the company's reliance on third parties for conducting clinical trials and manufacturing introduces further operational and supply chain risks.

AI Analysis | Feedback

null

AI Analysis | Feedback

Tarsus Pharmaceuticals (symbol: TARS) focuses on developing and commercializing therapeutic candidates for eye care and infectious disease prevention. The addressable markets for their main products and pipeline candidates are as follows:

XDEMVY (lotilaner ophthalmic solution) for Demodex Blepharitis

• Addressable Market Size: Approximately 25 million people in the U.S. suffer from Demodex blepharitis.
• Region: U.S.
• The global blepharitis drug market, which includes treatments for Demodex blepharitis, was valued at USD 1.14 billion in 2024 and is projected to reach USD 1.75 billion by 2033.

TP-04 for Ocular Rosacea

• Addressable Market Size: Ocular Rosacea affects an estimated 15-18 million Americans.
• Region: U.S.

TP-05 for Lyme Disease Prophylaxis

• Addressable Market Size: Estimates for annual cases of Lyme disease in the United States range from approximately 300,000 to 400,000.
• Region: U.S. (for annual cases). The broader Lyme disease market across the top 7 markets (US, EU4, UK, and Japan) reached USD 632.4 million in 2024 and is expected to reach USD 1,281.9 million by 2035.

TP-05 for Community Malaria Reduction

• Addressable Market Size: Globally, there are approximately 247 million malaria cases and more than 600,000 deaths worldwide.
• Region: Global

AI Analysis | Feedback

Tarsus Pharmaceuticals (NASDAQ: TARS) is expected to drive future revenue growth over the next 2-3 years through several key initiatives, primarily centered around its flagship product, XDEMVY, and the advancement of its pipeline:

1. Continued Robust Adoption and Increased Prescription Volumes of XDEMVY in the U.S. Market: XDEMVY, approved for Demodex blepharitis, is a significant revenue generator, with Tarsus reporting strong net product sales and bottle dispensations in its first full year in the market. The company is actively expanding its sales force, which grew from 100 to 150 representatives, and leveraging direct-to-consumer (DTC) campaigns to increase patient awareness and drive potential patients to eye care professional (ECP) offices. Tarsus also aims to encourage ECPs to move from monthly to more frequent prescribing patterns. The company has achieved broad commercial and Medicare coverage, extending to over 90% of covered lives.
2. International Expansion of XDEMVY: Tarsus is actively pursuing global market penetration for XDEMVY. The company anticipates a potential European regulatory submission in 2026, with approval expected in 2027, for a preservative-free formulation of XDEMVY. Additionally, discussions are ongoing with regulatory authorities in Japan to determine a path forward for Demodex blepharitis, and a marketing application for XDEMVY has been accepted in China. Successful expansion into these international markets would significantly broaden XDEMVY's revenue base.
3. Advancement and Potential Launch of Pipeline Products: Beyond XDEMVY, Tarsus is developing a robust pipeline of other potential category-creating therapeutics. Key candidates include TP-03 for the treatment of Meibomian Gland Disease (MGD), which is currently in Phase 2a clinical trials. The successful progression and potential launch of TP-03, particularly given its focus on eye care, within the 2-3 year timeframe could provide an additional stream of revenue. Tarsus is also advancing TP-04 for ocular rosacea and TP-05 for Lyme disease prevention, both in Phase 2a studies, demonstrating a broader therapeutic strategy for future growth.

AI Analysis | Feedback

Capital Allocation Decisions (2020-2025)

Share Issuance

• Tarsus Pharmaceuticals completed its Initial Public Offering (IPO) in October 2020, offering 6,325,000 shares of common stock at $16.00 per share, resulting in approximately $101.2 million in gross proceeds.
• In March 2024, the company completed a public offering of 3,281,250 shares of common stock and pre-funded warrants, generating approximately $107.8 million in net proceeds.
• Tarsus Pharmaceuticals priced an upsized underwritten public offering in March 2025, selling 2,808,988 shares of common stock at $44.50 per share, which was expected to raise approximately $125.0 million in gross proceeds, with an option for underwriters to purchase additional shares. This offering strengthened their financial position with $134.8 million in proceeds.

Inbound Investments

• In January 2020, Tarsus Pharmaceuticals completed a $60 million Series B financing round. The financing was led by Vivo Capital, with participation from Frazier Healthcare Partners, Flying L Partners, Visionary Ventures, Aperture Venture Partners, and Horowitz Group. These funds were earmarked to support a Phase 2b/3 trial for their lead product TP-03 and other clinical pipeline development.
• Institutional investors hold a significant stake in Tarsus Pharmaceuticals, owning 90.01% of the company's stock as of November 2025.
• Vanguard Group Inc. made a significant acquisition on September 30, 2024, acquiring 2,097,323 shares of Tarsus Pharmaceuticals Inc.

Outbound Investments

• Tarsus Pharmaceuticals has made no investments or acquisitions in other companies.

Capital Expenditures

• Tarsus Pharmaceuticals Inc.'s capital expenditures for fiscal years ending December 2020 to 2024 averaged 923.4 thousand, peaking in December 2024 at $1.567 million.
• In the last 12 months (as of current time in November 2025), capital expenditures were -$6.95 million.
• Primary focus of capital allocation includes advancing its pipeline, specifically the progression of TP-04 for ocular rosacea, maintaining the expansion of XDEMVY, and investing in international market regulatory sessions.